Dengvaxia: the world’s first vaccine for prevention of secondary dengue
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was cond...
Main Authors: | Danielle Tully, Carrie L. Griffiths |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-05-01
|
Series: | Therapeutic Advances in Vaccines and Immunotherapy |
Online Access: | https://doi.org/10.1177/25151355211015839 |
Similar Items
-
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
by: Jedhan Ucat Galula, et al.
Published: (2019-10-01) -
Optimal Control of a Dengue-Dengvaxia Model: Comparison Between Vaccination and Vector Control
by: Mentuda Cheryl Q.
Published: (2021-11-01) -
A multi-country study of dengue vaccination strategies with Dengvaxia and a future vaccine candidate in three dengue-endemic countries: Vietnam, Thailand, and Colombia
by: Lee, J, et al.
Published: (2018) -
A review of Dengvaxia®: development to deployment
by: Stephen J. Thomas, et al.
Published: (2019-10-01) -
Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines
by: Yu-Ching Dai, et al.
Published: (2023-07-01)